On Monday, Taysha Gene Therapies Inc (NASDAQ: TSHA) opened lower -2.90% from the last session, before settling in for the closing price of $2.07. Price fluctuations for TSHA have ranged from $1.19 to $4.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 129.39%. Company’s average yearly earnings per share was noted 61.46% at the time writing. With a float of $153.61 million, this company’s outstanding shares have now reached $204.94 million.
The extent of productivity of a business whose workforce counts for 52 workers is very important to gauge. In terms of profitability, gross margin is 90.01%, operating margin of -880.73%, and the pretax margin is -229.67%.
Taysha Gene Therapies Inc (TSHA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Taysha Gene Therapies Inc is 25.05%, while institutional ownership is 69.54%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 61.46% per share during the next fiscal year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Check out the current performance indicators for Taysha Gene Therapies Inc (TSHA). In the past quarter, the stock posted a quick ratio of 5.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 41.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.03, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
The latest stats from [Taysha Gene Therapies Inc, TSHA] show that its last 5-days average volume of 4.02 million was superior to 2.86 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 4.22%. Additionally, its Average True Range was 0.25.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 38.68%, which indicates a significant increase from 2.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.39% in the past 14 days, which was lower than the 102.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.13, while its 200-day Moving Average is $2.44. Now, the first resistance to watch is $2.10. This is followed by the second major resistance level at $2.19. The third major resistance level sits at $2.25. If the price goes on to break the first support level at $1.95, it is likely to go to the next support level at $1.88. The third support level lies at $1.79 if the price breaches the second support level.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are currently 204,943K shares outstanding in the company with a market cap of 411.94 million. Presently, the company’s annual sales total 15,450 K according to its annual income of -111,570 K. Last quarter, the company’s sales amounted to 1,790 K and its income totaled -25,520 K.
